Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The expression of Epidermal Growth Factor Receptor (EGF-R) in gynecological malignant tumors was investigated immunohistochemically. 1) With respect to the expression of EGF-R in the uterine cervix, it was seen in 20.0% with benign lesion. In cases of dysplasia, it was expressed in 62.5% of the cases with mild dysplasia, 81.8% with moderate dysplasia and 53.3% with severe dysplasia. In cases of CIS, it was seen in 46.7% and in cases of invasive cancer, it was seen in 22.2%. By hystological type, the expression rates were 27.3% for keratinized squamous cell carcinoma and 33.3% for large cell non-keratinized squamous cell carcinoma. No expression was seen in three cases of small cell non-keratinized squamous cell carcinoma or four cases of adenocarcinoma. In cases of benign lesions, EGF-R was localized in the cell walls of the basal layer, but in cases with dysplasia, it was found in the cell walls and also in the cytoplasm in all layers of the epithelium. 2) The expression rate in endometrial carcinoma was 14.3% and all of these cases were well-differentiated adenocarcinoma. There was no reverse correlation with estrogen receptors. 3) The expression rate for advanced malignant ovarian tumors was 31.4% and there was no clear correlation with the histological type. The prognosis tended to be better in cases expressing EGF-R than in those not. These results indicated that EGF-R appears to be related to the degree of advance of cervical dysplasia, but it was clear that the frequency of expression of EGF-R decreased when the cancer became invasive. In cases of malignant ovarian tumors, the expression of EGF-R tended to be related to the prognosis.
 ...
PMID:[Immunohistochemical studies on epidermal growth factor receptor (EGF-R) in gynecological malignant tumor]. 206 13

Large granular lymphocytes (LGL) containing almost all natural killer (NK) and killer (K) cells were studied in the peripheral blood of patients with gynecological malignancies. The results obtained were as follows: The ratio of LGL/peripheral blood lymphocytes (PBL) in normal volunteers was almost the same as that in patients with benign gynecological tumors, showing a tendency to increase, though not significantly, with age. The ratio of patients with precancerous disease or preinvasive cancer, including severe dysplasia, CIS and endometrial atypical hyperplasia, decreased more slightly than that of controls. On the other hand, that of patients with invasive malignant tumors, including uterine cervical cancer, endometrial cancer, uterine sarcoma, ovarian cancer and vulval cancer, increased significantly more than that of controls. The ratio showed no significant variation due to the difference in tumor sites and clinical stages Ia to III of cervical cancer. Out of 8 patients with ovarian cancer, 6 showed an extraordinarily high LGL/PBL ratio. It is concluded from the present study that the increase in the LGL/PBL ratio may be used as a new criterion in diagnosing invasive malignancies, including ovarian cancer, although the significance of the changing ratio still remains to be clarified.
 ...
PMID:[Large granular lymphocytes (LGL) in the peripheral blood of patients with gynecological malignancies]. 666 28

The single most common cause leading to the diagnosis of endometrial cancer is postmenopausal bleeding. Although most patients with early-stage disease (FIGO stage I and II) can be cured, prognosis worsens considerably with increasing stage. While serum CA 125 levels are elevated only in a significant proportion of patients with advanced disease, recently a new serum marker (OVX1) for the detection of early-stage endometrial cancer was reported. Serum OVX1 levels were measured using an OVX1 radioimmunoassay (RIA) or enzyme immunoassay (EIA) in 192 patients with endometrial cancer. CA 125 levels were measured in 112 patients using the CIS ELSA CA 125 kit. Apparently healthy females had mean serum OVX1 levels measured with the OVX1-EIA of 1.34 +/- 0.74 U/ml, while patients with endometriosis had mean OVX1 serum levels of 3.15 +/- 2.45 U/ml. The mean OVX1 serum level for endometrial cancer patients was 2.00 +/- 1.32 U/ml. These values were 2.76 +/- 1.62, 6.10 +/- 4.66, and 5.37 +/- 3.49, respectively, using the OVX1-RIA assay. Applying a cutoff value of 2.8 U/ml, serum OVX1-EIA levels in endometrial cancer patients were increased in 25 of 127 patients (19.7%) with stage I disease, 5 of 17 patients with stage II (29.4%), 5 of 22 patients (22.7%) with stage III, and 4 of 11 patients (36.4%) with stage IV disease. Using the OVX1-RIA and a cutoff of 7.2 U/ml, serum levels were increased in 22 of 127 (17.3%) stage I, 6 of 17 (35.3%) stage II, 5 of 22 (22.7%) stage III, and 6 of 11 (54.5%) stage IV patients. Serum CA 125 levels, determined in a total of 112 patients, were elevated above 35 U/ml in 12 of 79 patients (15.2%) with stage I, 4 of 12 patients (33.3%) with stage II, 8 of 13 patients (61.5%) with stage III, and all of 8 patients (100%) with stage IV disease. While a good correlation between serum CA 125 levels and the clinical stage of the disease was found, no correlation could be detected for OVX1 and stage.
 ...
PMID:Is OVX1 a suitable marker for endometrial cancer? 915 40

We have examined telomerase activities in uterine cancer specimens including non-cancerous normal counterparts by the method of TRAP assay. We detected strong telomerase activities in 29 of 30 cervical cancers (96.7%) and all 16 samples of endometrial cancer. Normal cervical epithelial tissues obtained from 5 individuals had very little telomerase activity but were evaluated to be diagnostically negative in the activity. In contrast, normal endometrial tissue specimens (4 out of 6) had relatively stronger telomerase activities in consistent with the result reported previously by others. Most notably, we found that dysplastic lesions in the uterine cervix had significant telomerase activities. In an attempt to examine the telomerase assay by using cervical scraping samples, we have detected the telomerase activity in one case of 12 (8.3%) normal cervical epithelia, one of 16 (6.3%) cervical dysplasias and 6 of 9 (66.7%) cervical cancers (stage 0-1b). These present study shows that the telomerase assay is useful for the diagnosis of cervical cancers. However, it is hampered to evaluate whether or not telomerase activity in endometrial cancer specimens is attributable to cancer cells because of the presence of relatively strong telomerase activity in normal endometrium. In addition, telomerase activities was detectable in scraping samples from uterine cervix which were clinically diagnosed as CIS but not dysplasia and normal.
 ...
PMID:[Telomerase activity in the uterine cervix and the uterine body]. 961 42